New Delhi, Aug. 8 -- Artificial intelligence (AI) is rapidly becoming a core part of pharmaceutical research and development (R&D), moving beyond its role as an experimental technology to help companies accelerate drug discovery, improve research productivity and make better scientific decisions, according to a report by AI platform Prezent Vivo.

The report said AI is transforming how biopharmaceutical companies identify promising drug targets, design new molecules and decide which drug candidates should move forward for preclinical research and clinical trials.

It added that AI is now influencing R&D investments, development timelines, talent strategies and decision-making across pharmaceutical organisations.

According to the report, ...